Of at least 24 biotech IPOs in 2012, 10 were completed in 4Q, raising $309.6 million. For the year, 24 deals raised $1.1 billion, compared with at least 19 that raised $972.7 million in 2011. The class of 2012 companies are up a median of 22%, led by the more than 2X increase in market value of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT). In December 2012, Intercept completed enrollment of 218 patients in the Phase III POISE trial of its lead compound, obeticholic acid, to treat primary biliary cirrhosis (PBC). Data are expected in 2Q14.

The 4Q12 IPOs are up 24%, compared to the 4% decline in the BioCentury 100 last quarter. The index was up 26% in 2012.

(A) In accordance with Taiwanese regulations, shares are sold at a substantial discount to the price at which they were trading on the GreTai Emerging market; (B) Includes shares sold in concurrent private placement; (C) Median percent change; $M; Source: BCIQ: BioCentury Online Intelligence

Company

Date

Raised

Post-$

12/31 mcap

% chg

Taiwan Liposome Co. Ltd. (GreTai:4152) (A)

12/21/12

$25.1

$239.3

$490.6

105%

UMN Pharma Inc. (Tokyo:4585)

12/11/12

$2.4

$109.1

$128.7

18%

Theradiag (Euronext:ALTER)

12/6/12

$10.7

$28.4

$27.4

-4%

Gene Techno Science Co. Ltd. (Tokyo:4584)

11/30/12

$8.4

$28.3

$36.7

29%

Atossa Genetics Inc. (NASDAQ:ATOS)

11/8/12

$4.0

$64.6

$50.4

-22%

Nanobiotix S.A. (Euronext:NANO)

10/24/12

$18.5

$83.5

$94.3

13%

Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH)

10/16/12

$81.0

$288.4

$552.5

92%

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)

10/15/12

$86.3

$247.3

$565.4

129%

Novacyt S.A. (Euronext:ALNOV)

10/8/12

$3.3

$28.5

$28.9

2%

Regulus Therapeutics Inc. (NASDAQ:RGLS)

10/4/12

$70.0

$136.5

$225.7

65%

Clinigen Group plc (LSE:CLIN)

9/19/12

$16.2

$219.6

$284.7

30%

PharmaEngine Inc. (GreTai:4162)

9/18/12

$31.7

$269.8

$557.9

107%

Hyperion Therapeutics Inc. (NASDAQ:HPTX)

7/26/12

$57.5

$165.9

$187.2

13%

Durata Therapeutics Inc. (NASDAQ:DRTX)

7/19/12

$77.6

$165.3

$140.4

-15%

Tesaro Inc. (NASDAQ:TSRO)

6/27/12

$86.8

$365.9

$459.8

26%

Retroscreen Virology Group plc (LSE:RVG)

5/3/12

$24.4

$53.4

$91.1

71%

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)

5/1/12

$52.2

$121.9

$218.4

79%

DBV Technologies (Euronext:DBV)

3/28/12

$53.8

$157.3

$145.1

-8%

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK)

3/28/12

$100.1

$646.8

$573.6

-11%

Adocia S.A.S. (Euronext:ADOC)

2/14/12

$36.3

$130.3

$81.8

-37%

ChemoCentryx Inc. (NASDAQ:CCXI) (B)

2/8/12

$63.8

$359.3

$396.7

10%

Beijing Leadman Biochemistry Co. Ltd. (SZSE:300289)

2/7/12

$79.2

$316.9

$564.5

78%

Cempra Inc. (NASDAQ:CEMP)

2/2/12

$58.0

$126.2

$159.4

26%

Verastem Inc. (NASDAQ:VSTM)

1/26/12

$63.3

$210.6

$186.8

-11%

4Q12 total (10 deals)

$309.6

$1,253.8

$2,200.7

24% (C)

2012 total (24 deals)

$1,110.5

$4,562.9

$6,248.0

22% (C)